News & Updates
Search Research Content
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
|Title||Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.|
|Publication Type||Journal Article|
|Year of Publication||2000|
|Authors||Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L|
|Journal||Journal of the National Cancer Institute|
|Date Published||2000 Jun 7|
Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast cancer. However, tamoxifen therapy induces high levels of plasma estradiol, with unknown long-term effects. In this study, we investigated the effect of combining estrogen suppression with the luteinizing hormone-releasing hormone agonist buserelin and estradiol receptor blockade with tamoxifen to determine whether the high estradiol levels induced by tamoxifen could be reduced and whether the antitumor effects would be better.
|Alternate Journal||J. Natl. Cancer Inst.|